PT  - JOURNAL ARTICLE
AU  - Hernandez, Matthew M.
AU  - Banu, Radhika
AU  - Gonzalez-Reiche, Ana S.
AU  - van de Guchte, Adriana
AU  - Khan, Zenab
AU  - Shrestha, Paras
AU  - Cao, Liyong
AU  - Chen, Feng
AU  - Shi, Huanzhi
AU  - Hanna, Ayman
AU  - Alshammary, Hala
AU  - Fabre, Shelcie
AU  - Amoako, Angela
AU  - Obla, Ajay
AU  - Alburquerque, Bremy
AU  - Helena Patiño, Luz
AU  - Ramírez, Juan David
AU  - Sebra, Robert
AU  - Gitman, Melissa R.
AU  - Nowak, Michael D.
AU  - Cordon-Cardo, Carlos
AU  - Schutzbank, Ted E.
AU  - Simon, Viviana
AU  - van Bakel, Harm
AU  - Sordillo, Emilia Mia
AU  - Paniz-Mondolfi, Alberto E.
TI  - Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multi-target approach
AID  - 10.1101/2021.09.09.21263348
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.09.21263348
4099  - http://medrxiv.org/content/early/2021/09/16/2021.09.09.21263348.short
4100  - http://medrxiv.org/content/early/2021/09/16/2021.09.09.21263348.full
AB  - The COVID-19 pandemic sparked rapid development of SARS-CoV-2 diagnostics. However, emerging variants pose the risk for target dropout and false-negative results secondary to primer/probe binding site (PBS) mismatches. The Agena MassARRAY® SARS-CoV-2 Panel combines RT-PCR and MALDI-TOF mass-spectrometry to probe for five targets across N and ORF1ab genes, which provides a robust platform to accommodate PBS mismatches in divergent viruses. Herein, we utilize a deidentified dataset of 1,262 SARS-CoV-2-positive specimens from Mount Sinai Health System (New York City) from December 2020 through April 2021 to evaluate target results and corresponding sequencing data. Overall, the level of PBS mismatches was greater in specimens with target dropout. Of specimens with N3 target dropout, 57% harbored an A28095T substitution that is highly-specific for the alpha (B.1.1.7) variant of concern. These data highlight the benefit of redundancy in target design and the potential for target performance to illuminate the dynamics of circulating SARS-CoV-2 variants.Competing Interest StatementRobert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai. Otherwise, the authors declare no competing interests.Funding StatementThe Research reported in this paper was supported by the National Institutes of Health (NIH) contract number HHSN272201400008C, the NIH Office of Research Infrastructure under award numbers S10OD018522 and S10OD026880, institutional and philanthropic funds (Open Philanthropy Project, #2020-215611), as well as a Robin Chemers Neustein Postdoctoral Fellowship Award (to Dr. Gonzalez-Reiche).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (HS#13-00981).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 sequencing read data for all study genomes were deposited in GISAID [www.gisaid.org] (accessions pending).